Clinical Trial Update: Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab and/or niraparib in patients with recurrent endometrial and/or ovarian cancer harboring ARID1A mutation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Zejula (Niraparib)

Snippet

Sponsor: University of Oklahoma | Conditions: Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: TERMINATED